A placebo-controlled, dose-ranging proof-of-principle trial of Col-Treg in autoimmune uveitis

Trial Profile

A placebo-controlled, dose-ranging proof-of-principle trial of Col-Treg in autoimmune uveitis

Planning
Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Col-Treg (Primary)
  • Indications Immune-mediated uveitis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 18 Mar 2015 According to a company media release, TxCell plans to initiate this study in the first-half of 2015.
    • 27 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top